The superintendent pharmacist of LloydsPharmacy, Steve Howard, has written to The Times calling for “more clinically appropriate and accurate coverage about EHC” in the wake of last week’s row about pricing in community pharmacy.

In his letter, Mr Howard said he was concerned that readers could have been misled by an article appearing in the July 27 edition of The Times, headlined ’Boots urged to act as rival chemist cuts costs of morning after pill’.

“As healthcare professionals, our priority is to ensure that women have access to the most appropriate and effective EHC products. I believe this article missed an opportunity to explain that the cheapest products aren’t necessarily always the most appropriate. Pricing of the pill, whilst important, should be the secondary issue.

“Our most important consideration – and that for any healthcare professional – is doing what is right for the patient, regardless of price. Through a consultation with one of our pharmacists, they can offer advice and guidance that best meets the needs of the patient, which could be referral to a doctor.”

Pharmacists are also ideally placed to talk to patients about contraception and sexually
transmitted infections, both of which are important associated topics, he added.

LloydsPharmacy intends to sell the generic EHC Ezinelle from September at a retail price of £13.49.

 

Recommended

Go green again for Pharmacist Support!

Pharmacist Support wants pharmacy teams to once again ’Go Green’ for annual fundraising campaign next month

First graduates from Nottingham’s integrated course ready to practise

Students from Nottingham are the first to graduate as qualified pharmacists after completing an integrated MPharm degree

Popular

Health checks and diabetes prevention New Style

This module provides an update on both the NHS Health Check and NHS diabetes prevention programmes

CPD: Anxiety disorders in adults New Style

This module will help you understand the main types of anxiety disorder and their therapeutic management

Dovonex is switched from POM to P

Dovonex Psoriasis Ointment (calcipotriol 50mcg/g) has been reclassified as a P medicine, the MHRA has announced